F D C

F D C OCF Margin

The Operating Cash Flow Margin of F D C (FDC.NS) as of Oct 25, 2026 is 15.06 %. In the previous year, Operating Cash Flow Margin was 11.36 % — a change of 32.58% (higher).

OCF Margin

15.06 %

YoY

32.58%

Last updated:

Operating Cash Flow Margin of F D C is 2025 15.06 % . Operating Cash Flow Margin of F D C was 2024 11.36 % . It decreases by 32.58% higher compared to the previous year.

The F D C OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
13.83 INR
Jan 1, 2019
10.31 INR
Jan 1, 2020
18.63 INR
Jan 1, 2021
15.53 INR
Jan 1, 2022
10.58 INR
Jan 1, 2023
8.68 INR
Jan 1, 2024
11.36 INR
Jan 1, 2025
15.06 INR
The F D C OCF Margin history
YEAROCF MarginYoY
15.06 %+32.58%
11.36 %+30.83%
8.68 %-17.91%
10.58 %-31.89%
15.53 %-16.61%
18.63 %+80.70%
10.31 %-25.49%
13.83 %-5.88%
14.70 %-14.20%
17.13 %+19.37%
14.35 %-18.92%
17.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

Operating Cash Flow Margin of F D C is 15.06 % in 2025.

Operating Cash Flow Margin of F D C changed from 11.36 % to 15.06 %, representing a 32.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin F D C since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's F D C with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — F D C

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — F D C